Research, the leading business intelligence provider, has released its latest research “The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research’s team of industry experts.
Scope
The scope of this report includes:
• Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
• Analysis of the leading therapeutic segments including diabetes and obesity.
• Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
For More Information Please Click :
http://www.aarkstore.com/reports/The-Future-of-Metabolic-Disorder-Therapeutics-M Or Call Us: 919272852585
Visit Our Blog: http://blogs.aarkstore.com
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research’s team of industry experts.
Scope
The scope of this report includes:
• Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
• Analysis of the leading therapeutic segments including diabetes and obesity.
• Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
For More Information Please Click :
http://www.aarkstore.com/reports/The-Future-of-Metabolic-Disorder-Therapeutics-M
Or Call Us: 919272852585
Visit Our Blog: http://blogs.aarkstore.com